 Since 2009 it was studied as a potential treatment option in multiple tumor types.By 2015 it had two US approvals for advanced cancers.Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer and has been approved by the US FDA on September 27, 2012.